Skip to main content

RapiDA

A powerful new tool in the
fight against Age-Related
Macular Degeneration (AMD),
a major global health problem

RapiDA

A powerful new tool in the
fight against Age-Related
Macular Degeneration (AMD),
a major global health problem

AMD: number one cause of sight loss or blindness in the developed world

RapiDA is a smart digital, early-alert screening process design to help tackle the debilitating disease that is AMD.

RapiDA’s innovative technology detects AMD at the earliest possible stage, when treatment can most effectively interrupt or slow down the progress of the disease.

In the garden as normal thanks to RapiDA

The importance of early detection

If detected late or not diagnosed at all, AMD leads to either debilitating sight loss or blindness. RapiDA has been developed to help prevent the disease from progressing this far.

Fast, affordable, simple to operate

RapiDA has been developed by a University of Manchester spin-out company, Mumac. Its patented technologies, which use dark adaptation, are affordable, simple to operate and provide fast results – screening can be completed in just five minutes.

The team behind RapiDA has considerable experience of developing specialist ophthalmic instruments and techniques. Other innovative ophthalmic products are currently in the Mumac pipeline.

Innovative, patented technologies designed to help AMD patients lead normal, full lives

Unique, real-time data, exceptional sensitivity and specificity

Streamlined, compact, ergonomically designed. Ideal for busy clinics.

Clinical trials

RapiDA has successfully undergone extensive clinical trials funded by the National Institute of Health Research (NIHR).
View results